Suzhou Basecare Medical Corporation Limited (HKG:2170)

HKG:2170 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	233.27	299.11	207.98	140.9	107.3
Revenue Growth (YoY)	-22.01%	43.82%	47.60%	31.32%	32.29%
Cost of Revenue	109.66	162.89	116.63	81.37	56.15
Gross Profit	123.61	136.22	91.35	59.53	51.15
Selling, General & Admin	221.97	276.39	209.3	161.5	114.64
Research & Development	106.42	135.26	129.57	119.77	73.71
Other Operating Expenses	-3.99	-7.63	-5.85	-5.7	-4.82
Operating Expenses	324.4	404.01	333.02	275.57	183.53
Operating Income	-200.79	-267.79	-241.67	-216.04	-132.38
Interest Expense	-26.23	-9.37	-2.61	-0.5	-1.26
Interest & Investment Income	11.8	25.27	38.51	23.62	18.2
Currency Exchange Gain (Loss)	-4.37	8.66	11.86	62.91	-10.31
Other Non Operating Income (Expenses)	3.12	-	-	-	-
EBT Excluding Unusual Items	-216.47	-243.24	-193.92	-130.01	-125.75
Gain (Loss) on Sale of Investments	-10.72	2.9	-2.4	3.4	-
Pretax Income	-227.19	-240.34	-196.32	-126.61	-125.75
Income Tax Expense	-3.74	-3.13	-2.97	6.01	18.33
Earnings From Continuing Operations	-223.46	-237.21	-193.35	-132.63	-144.08
Earnings From Discontinued Operations	-	-	-	9.12	-
Net Income to Company	-223.46	-237.21	-193.35	-123.51	-144.08
Minority Interest in Earnings	-	0.18	1.66	0.84	0.43
Net Income	-223.46	-237.03	-191.69	-122.66	-143.65
Net Income to Common	-223.46	-237.03	-191.69	-122.66	-143.65
Shares Outstanding (Basic)	274	274	274	274	265
Shares Outstanding (Diluted)	274	274	274	274	265
Shares Change (YoY)	-	-	-	3.09%	54.34%
EPS (Basic)	-0.82	-0.87	-0.70	-0.45	-0.54
EPS (Diluted)	-0.82	-0.87	-0.70	-0.45	-0.54
Free Cash Flow	-	-322.41	-371.44	-317.22	-226.75
Free Cash Flow Per Share	-	-1.18	-1.36	-1.16	-0.85
Gross Margin	52.99%	45.54%	43.92%	42.25%	47.67%
Operating Margin	-86.08%	-89.53%	-116.20%	-153.33%	-123.38%
Profit Margin	-95.79%	-79.25%	-92.17%	-87.06%	-133.88%
Free Cash Flow Margin	-	-107.79%	-178.60%	-225.14%	-211.33%
EBITDA	-170.6	-237.6	-227.18	-210.59	-129.5
EBITDA Margin	-73.13%	-79.44%	-109.23%	-149.46%	-120.69%
D&A For EBITDA	30.19	30.19	14.49	5.45	2.89
EBIT	-200.79	-267.79	-241.67	-216.04	-132.38
EBIT Margin	-86.08%	-89.53%	-116.20%	-153.33%	-123.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.